Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Nat Commun. 2021 Jun 21;12(1):3984. doi: 10.1038/s41467-021-24300-8.

Xuping Xie^#¹, Antonio E Muruato^#^{2

3}, Xianwen Zhang², Kumari G Lokugamage³, Camila R Fontes-Garfias², Jing Zou², Jianying Liu³, Ping Ren⁴, Mini Balakrishnan⁵, Tomas Cihlar⁵, Chien-Te K Tseng³, Shinji Makino³, Vineet D Menachery^{3

4

6}, John P Bilello⁷, Pei-Yong Shi^{8

9

10

11}

¹ Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. xuxie@UTMB.edu.
² Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
³ Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
⁴ Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
⁵ Gilead Sciences, Inc., Foster City, CA, USA.
⁶ Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
⁷ Gilead Sciences, Inc., Foster City, CA, USA. john.bilello@gilead.com.
⁸ Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. peshi@UTMB.edu.
⁹ Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. peshi@UTMB.edu.
¹⁰ Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. peshi@UTMB.edu.
¹¹ Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA. peshi@UTMB.edu.

^# Contributed equally.

No abstract available

Publication types